SCHEMBL4069886

SCHEMBL4069886

O=Cc1cncc(NC(=O)c2cc(Cl)cc(Cl)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.47
GRM5 P41594 4/20 0.44
HSD11B1 P28845 1/20 0.42
KDR P35968 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
KCNQ5 Q9NR82 1/20 0.40
GRM4 Q14833 1/20 0.40
NAMPT P43490 1/20 0.40
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22946413 0.78 HSD11B1 (0.49) CSF1RHSD11B1MEN1KMT2AGRM4
SCHEMBL13912207 0.77 CSF1R (0.47) CSF1RGRM5HSD11B1
SCHEMBL15652505 0.76 NPC1 (0.59) MEN1KMT2ANAMPT
SCHEMBL5779344 0.76 AKT1 (0.39) NAMPT
SCHEMBL15652470 0.74 LMNA (0.41) MEN1KMT2A
SCHEMBL13623453 0.71 SLC6A3 (0.46) CSF1RGRM5HSD11B1KDRMAOB
SCHEMBL6919417 0.68 GRM5 (0.65) GRM5
SCHEMBL15652275 0.68 RAF1 (0.51) MEN1KMT2ANAMPT
SCHEMBL23565963 0.68 CLK2 (0.49) MEN1KMT2A
SCHEMBL2825756 0.68 NAMPT (0.46) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8933012-B2 Glycopeptide antibiotic derivative SHIONOGI & CO., LTD. (JP) 2015-01-13 US disclosed
US-8933012-B2 Glycopeptide antibiotic derivative SHIONOGI & CO., LTD. (JP) 2015-01-13 US disclosed
US-8933012-B2 Glycopeptide antibiotic derivative SHIONOGI & CO., LTD. (JP) 2015-01-13 US disclosed
US-20090286717-A1 Glycopeptide Antibiotic Derivative SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286717-A1 Glycopeptide Antibiotic Derivative SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286717-A1 Glycopeptide Antibiotic Derivative SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
EP-2030982-A1 GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE SHIONOGI & CO., LTD. (JP) 2009-03-04 EP disclosed
EP-2030982-A1 GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE SHIONOGI & CO., LTD. (JP) 2009-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286717-A1 Glycopeptide Antibiotic Derivative NR2C2, NR0B2, NR3C2 CSF1R 355/4885GRM5 759/4885HSD11B1 215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.